Cargando…

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF gene will lead to cancer development and progression. In non-small cell lung cancer (NSCLC), BRAF mutations commonly occur in n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Ningning, Guo, Sanxing, Zhang, Huixian, Zhang, Ziheng, Shen, Shujing, Li, Xingya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008712/ https://www.ncbi.nlm.nih.gov/pubmed/35433454 http://dx.doi.org/10.3389/fonc.2022.863043

Ejemplares similares

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2022)

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2023)

A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer
por: Geng, Di, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
por: Takeda, Hiroyuki, et al.
Publicado: (2021)

Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review
por: Puri, Megha, et al.
Publicado: (2023)

The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer
por: Zhang, Longyao, et al.
Publicado: (2022)

Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma
por: Thrift, Aaron P., et al.
Publicado: (2012)

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation
por: Qu, Jingjing, et al.
Publicado: (2022)

Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future Directions
por: Zhang, Zhuo, et al.
Publicado: (2015)

Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer
por: Mu, Yuxin, et al.
Publicado: (2020)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives
por: Yang, Chaogang, et al.
Publicado: (2019)

In vitro models for head and neck cancer: Current status and future perspective
por: Moya-Garcia, Christian R., et al.
Publicado: (2022)

Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
por: Ottaiano, Alessandro, et al.
Publicado: (2022)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives
por: Li, Ling-Rui, et al.
Publicado: (2021)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China
por: Mizuno, Takaaki, et al.
Publicado: (2022)

Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI
por: Cai, Xiaomin, et al.
Publicado: (2022)

Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective
por: Salman, Pamela, et al.
Publicado: (2023)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
por: Li, Linlin, et al.
Publicado: (2023)

Genitourinary Oncology: Current Status and Future Challenges
por: Bukowski, Ronald M.
Publicado: (2011)

Radiation Metabolomics: Current Status and Future Directions
por: Menon, Smrithi S., et al.
Publicado: (2016)

BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?
por: Bouchè, Victoria, et al.
Publicado: (2021)

Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer
por: Mondelo-Macía, Patricia, et al.
Publicado: (2021)

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy
por: Banerjee, Natasha, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Modeling Radioimmune Response—Current Status and Perspectives
por: Friedrich, Thomas, et al.
Publicado: (2021)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients
por: Guan, Wen-Long, et al.
Publicado: (2020)

Current status and future perspectives of liquid biopsy in non-small cell lung cancer
por: Chang, Sunhee, et al.
Publicado: (2020)

Circular RNAs in Lung Cancer: Recent Advances and Future Perspectives
por: Chen, Huan-Huan, et al.
Publicado: (2021)

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
por: Liu, Chaoyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1s8rrd0flrer9i8dfgue7hpl0r